Mostrar el registro sencillo del ítem

dc.contributor.author
Ferré, Sergi  
dc.contributor.author
Belcher, Annabelle M.  
dc.contributor.author
Bonaventura, Jordi  
dc.contributor.author
Quiroz, César  
dc.contributor.author
Sánchez Soto, Marta  
dc.contributor.author
Casadó Anguera, Verónica  
dc.contributor.author
Cai, Ning Sheng  
dc.contributor.author
Moreno, Estefanía  
dc.contributor.author
Boateng, Comfort A.  
dc.contributor.author
Keck, Thomas M.  
dc.contributor.author
Florán, Benjamín  
dc.contributor.author
Earley, Christopher J.  
dc.contributor.author
Ciruela, Francisco  
dc.contributor.author
Casadó, Vincet  
dc.contributor.author
Rubinstein, Marcelo  
dc.contributor.author
Volkow, Nora D.  
dc.date.available
2024-07-24T15:38:45Z  
dc.date.issued
2022-09-30  
dc.identifier.citation
Ferré, Sergi; Belcher, Annabelle M.; Bonaventura, Jordi; Quiroz, César; Sánchez Soto, Marta; et al.; Functional and pharmacological role of the dopamine D4 receptor and its polymorphic variants; Frontiers Media; Frontiers in Endocrinology; 13; 30-9-2022; 1-14  
dc.identifier.uri
http://hdl.handle.net/11336/240776  
dc.description.abstract
The functional and pharmacological significance of the dopamine D4 receptor (D4R) has remained the least well understood of all the dopamine receptor subtypes. Even more enigmatic has been the role of the very prevalent human DRD4 gene polymorphisms in the region that encodes the third intracellular loop of the receptor. The most common polymorphisms encode a D4R with 4 or 7 repeats of a proline-rich sequence of 16 amino acids (D4.4R and D4.7R). DRD4 polymorphisms have been associated with individual differences linked to impulse control-related neuropsychiatric disorders, with the most consistent associations established between the gene encoding D4.7R and attention-deficit hyperactivity disorder (ADHD) and substance use disorders. The function of D4R and its polymorphic variants is being revealed by addressing the role of receptor heteromerization and the relatively avidity of norepinephrine for D4R. We review the evidence conveying a significant and differential role of D4.4R and D4.7R in the dopaminergic and noradrenergic modulation of the frontal cortico-striatal pyramidal neuron, with implications for the moderation of constructs of impulsivity as personality traits. This differential role depends on their ability to confer different properties to adrenergic α2A receptor (α2AR)-D4R heteromers and dopamine D2 receptor (D2R)-D4R heteromers, preferentially localized in the perisomatic region of the frontal cortical pyramidal neuron and its striatal terminals, respectively. We also review the evidence to support the D4R as a therapeutic target for ADHD and other impulse-control disorders, as well as for restless legs syndrome.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Frontiers Media  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/  
dc.subject
Drd4  
dc.subject
DOPAMINE  
dc.subject
RATÓN MUTANTE  
dc.subject
ADHD  
dc.subject.classification
Bioquímica y Biología Molecular  
dc.subject.classification
Ciencias Biológicas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
Functional and pharmacological role of the dopamine D4 receptor and its polymorphic variants  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2024-06-25T14:05:53Z  
dc.identifier.eissn
1664-2392  
dc.journal.volume
13  
dc.journal.pagination
1-14  
dc.journal.pais
Suiza  
dc.journal.ciudad
Lausana  
dc.description.fil
Fil: Ferré, Sergi. National Institutes on Drug Abuse; Estados Unidos  
dc.description.fil
Fil: Belcher, Annabelle M.. University of Maryland; Estados Unidos  
dc.description.fil
Fil: Bonaventura, Jordi. National Institutes on Drug Abuse; Estados Unidos. Universidad de Barcelona; España  
dc.description.fil
Fil: Quiroz, César. National Institutes on Drug Abuse; Estados Unidos  
dc.description.fil
Fil: Sánchez Soto, Marta. National Institutes on Drug Abuse; Estados Unidos  
dc.description.fil
Fil: Casadó Anguera, Verónica. Universidad de Barcelona; España  
dc.description.fil
Fil: Cai, Ning Sheng. National Institutes on Drug Abuse; Estados Unidos  
dc.description.fil
Fil: Moreno, Estefanía. Universidad de Barcelona; España  
dc.description.fil
Fil: Boateng, Comfort A.. High Point University. Fred Wilson School of Pharmacy.; Estados Unidos  
dc.description.fil
Fil: Keck, Thomas M.. Rowan University; Reino Unido  
dc.description.fil
Fil: Florán, Benjamín. Instituto Politécnico Nacional. Centro de Investigación y de Estudios Avanzados; México  
dc.description.fil
Fil: Earley, Christopher J.. University Johns Hopkins; Estados Unidos  
dc.description.fil
Fil: Ciruela, Francisco. Universidad de Barcelona; España  
dc.description.fil
Fil: Casadó, Vincet. Universidad de Barcelona; España  
dc.description.fil
Fil: Rubinstein, Marcelo. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina  
dc.description.fil
Fil: Volkow, Nora D.. National Institutes of Health; Estados Unidos  
dc.journal.title
Frontiers in Endocrinology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fendo.2022.1014678/full  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fendo.2022.1014678